Suppr超能文献

血管免疫母细胞性淋巴结病伴蛋白血症与癌相关。病例报告及文献复习。

Angioimmunoblastic lymphadenopathy with disproteinemia associated with carcinoma. Case report and review of the literature.

作者信息

Cavanna L, Di Stasi M, Paties C, Fornari F, Civardi G, Sbolli G, Buscarini L

机构信息

Prima Divisione Medica, Ospedale Civile di Piacenza, Italia.

出版信息

Oncology. 1988;45(4):318-21. doi: 10.1159/000226631.

Abstract

Angioimmunoblastic lymphadenopathy with disproteinemia (AILD) is a rare lymphoproliferative disorder. The clinical course varies and about 15-20% of the patients develop a malignant lymphoma. The association of AILD and carcinoma is very rare: only 4 cases have been reported in the literature. They are reviewed here and 1 case is described. This case is of special interest for the following reasons: (1) the exceptional length of time which elapsed between the diagnosis of AILD and the onset of an adenocarcinoma of the colon (118 months); (2) the long survival (the patient is still alive and well 140 months after the diagnosis of AILD); (3) unlike the cases reviewed, in our patient the carcinoma was diagnosed when AILD was in clinical remission, so a radical treatment was possible. In the cases previously reported, carcinomas arose in the lung (2 patients), pancreas (1 case), and stomach (1 case). The rare association of AILD and carcinoma is probably coincidental; however, the growth of solid tumors of nonlymphoid nature may be related to the impaired T cell function, and should be kept in mind in the management of patients with AILD.

摘要

血管免疫母细胞性淋巴结病伴蛋白异常血症(AILD)是一种罕见的淋巴增殖性疾病。其临床病程各异,约15% - 20%的患者会发展为恶性淋巴瘤。AILD与癌的关联极为罕见:文献中仅报道了4例。本文对这些病例进行回顾并描述1例。该病例因以下原因而特别引人关注:(1)从AILD诊断到结肠腺癌发病间隔时间异常长(118个月);(2)生存期长(患者在AILD诊断后140个月仍然健在);(3)与所回顾的病例不同,我们的患者在AILD临床缓解期诊断出癌,因此有可能进行根治性治疗。在先前报道的病例中,癌分别发生于肺(2例患者)、胰腺(1例)和胃(1例)。AILD与癌的罕见关联可能是巧合;然而,非淋巴样实体瘤的生长可能与T细胞功能受损有关,在AILD患者的管理中应予以考虑。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验